Clinical Trial Update: Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune Score [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating fruquintinib plus a PD-1 antibody in locally advanced rectal cancer with pMMR/MSS and high immune score.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Fruquintinib (fruquintinib)
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Locally Advanced Rectal Cancer | Phase 2 | Status: UNKNOWN